Oncolytics Biotech (ONCY) News Today $0.98 -0.03 (-2.97%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond JamesRaymond James upgraded shares of Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday.November 16 at 6:18 AM | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Leede FinancialLeede Financial lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a report on Wednesday.November 16 at 6:17 AM | marketbeat.comFY2024 Earnings Estimate for ONCY Issued By Raymond JamesNovember 16 at 1:57 AM | americanbankingnews.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call TranscriptNovember 15 at 9:08 AM | insidermonkey.comWhat is Raymond James' Estimate for ONCY FY2024 Earnings?Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at Raymond James dropped their FY2024 earnings per share estimates for Oncolytics Biotech in a research report issued to clients and investors on Tuesday, November 12th. Raymond James analyst R. Sarugaser now expects that the coNovember 15 at 6:52 AM | marketbeat.comOncolytics Biotech's (ONCY) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday.November 14 at 8:57 AM | marketbeat.comOncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comOncolytics Biotech Reports Promising Cancer Treatment ResultsNovember 12, 2024 | markets.businessinsider.comOncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational HighlightsNovember 12, 2024 | prnewswire.comOncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational HighlightsNovember 11, 2024 | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short InterestOncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 2,650,000 shares, an increase of 159.8% from the September 30th total of 1,020,000 shares. Based on an average daily volume of 405,900 shares, the days-to-cover ratio is presently 6.5 days.October 26, 2024 | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Down 5.3% - Here's WhyOncolytics Biotech (NASDAQ:ONCY) Shares Down 5.3% - Time to Sell?October 11, 2024 | marketbeat.comOncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval PathOctober 4, 2024 | prnewswire.comPromising Progress in Oncology as Cancer Deaths Decline and Research GrowsSeptember 24, 2024 | baystreet.caHow Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for BiotechsSeptember 20, 2024 | tmcnet.comBuy Rating Affirmed on Oncolytics Biotech Following Promising Pelareorep Clinical DataSeptember 20, 2024 | markets.businessinsider.comOncolytics Biotech reports positive results from breast cancer studySeptember 19, 2024 | msn.comOncolytics Biotech (NASDAQ:ONCY) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of Oncolytics Biotech in a report on Thursday.September 19, 2024 | marketbeat.comOncolytics Biotech Reports Favorable Results For Breast Cancer StudySeptember 19, 2024 | markets.businessinsider.comOncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling StudySeptember 19, 2024 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Down 0.7%Oncolytics Biotech (NASDAQ:ONCY) Trading Down 0.7%September 17, 2024 | marketbeat.comOncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in SeptemberSeptember 6, 2024 | prnewswire.comHC Wainwright Analysts Decrease Earnings Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY)Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Oncolytics Biotech in a report released on Wednesday, August 21st. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings pAugust 23, 2024 | marketbeat.comOptimistic Outlook for Oncolytics Biotech with Continued Buy Rating Amidst Promising Trial ResultsAugust 15, 2024 | markets.businessinsider.comBiotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient OutcomesAugust 12, 2024 | baystreet.caAnalysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), R1 RCM (RCM) and Lumos Pharma (LUMO)August 7, 2024 | markets.businessinsider.comBuy Rating on Oncolytics Biotech Backed by Strong Clinical Trials and Strategic PartnershipsAugust 3, 2024 | markets.businessinsider.comOncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth ConferenceAugust 2, 2024 | prnewswire.comOncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | seekingalpha.comOncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational HighlightsAugust 1, 2024 | prnewswire.comClosing Bell: Oncolytics Bio up on Thursday (ONC)July 26, 2024 | theglobeandmail.comOncolytics Biotech (ONCY) Scheduled to Post Quarterly Earnings on ThursdayOncolytics Biotech (NASDAQ:ONCY) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.July 25, 2024 | marketbeat.comOncolytics Biotech (ONCY) Set to Announce Earnings on ThursdayOncolytics Biotech (NASDAQ:ONCY) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.July 25, 2024 | marketbeat.comOncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational HighlightsJuly 24, 2024 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Down 1%Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1%July 23, 2024 | marketbeat.comOncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramJune 27, 2024 | prnewswire.comOncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of AbsenceJune 24, 2024 | prnewswire.comOncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic CancerJune 20, 2024 | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Short Interest Down 23.9% in MayOncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) saw a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 659,000 shares, a decrease of 23.9% from the May 15th total of 866,100 shares. Based on an average daily trading volume, of 217,000 shares, the days-to-cover ratio is presently 3.0 days.June 15, 2024 | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Shares Down 0.9% Oncolytics Biotech (NASDAQ:ONCY) Trading Down 0.9%June 7, 2024 | marketbeat.comAdvancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology ConferenceMay 24, 2024 | msn.comOncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic CancerMay 24, 2024 | finance.yahoo.comOncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of ActionMay 24, 2024 | prnewswire.comFY2024 Earnings Forecast for Oncolytics Biotech Inc. (NASDAQ:ONCY) Issued By HC WainwrightOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a report released on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.2May 16, 2024 | marketbeat.comOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersMay 16, 2024 | prnewswire.comFY2028 EPS Estimates for Oncolytics Biotech Inc. (NASDAQ:ONCY) Cut by AnalystOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright reduced their FY2028 earnings estimates for Oncolytics Biotech in a research report issued on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $May 15, 2024 | marketbeat.comOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer TrialMay 15, 2024 | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational HighlightsMay 9, 2024 | prnewswire.comOncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic CancerMay 9, 2024 | prnewswire.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now ONCY Media Mentions By Week ONCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCY News Sentiment▼0.020.56▲Average Medical News Sentiment ONCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCY Articles This Week▼171▲ONCY Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enlivex Therapeutics News Today Sage Therapeutics News Today Voyager Therapeutics News Today Alpha Teknova News Today YS Biopharma News Today Kamada News Today Jasper Therapeutics News Today iTeos Therapeutics News Today Aurora Cannabis News Today Biomea Fusion News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
